Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of DebtUnprecedented Quarter Shows Company’s Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational Beverage and Alcohol Metabolizer\n\n\n\n TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“\n \n Quantum BioPharma\n \n ” or the “\n \n Company\n \n ”), is pleased to announce its financial and operational results for the second quarter ending June 30, 2025.\n \n\n Overall, the Company is in a strong position having increased its current and total assets, compared to the previous quarter; eliminated the entire debt liability associated with debentures issued in Q4 2024 and Q1 2025 by converting all debentures into equity; maintained its ‘no going concern’ status; seen greater than $500,000 USD appreciation in the value of its cryptocurrency reserves as of date of filing; and seen its stock price almost tripled from $7.71 USD at Q1 close March 31, 2025 to $20.25 USD at Q2 close June 30, 2025. Management believes that there is sufficient cash on hand to maintain basic operations beyond March 2027.\n \n\n Meanwhile, the Company continues to advance clinical trials of its potential breakthrough multiple sclerosis drug, Lucid-21-302 (“Lucid-MS”), an oral-formulation drug that has shown, in pre-clinical animal studies, to stop nerve demyelination – the hallmark of multiple sclerosis. Phase 1 oral toxicity studies of Lucid-MS are complete and show no toxicity or side effects of the drug. In a joint study with Massachusetts General Hospital, the first person with multiple sclerosis (MS) has been scanned using a possible breakthrough PET scan imaging technique to monitor demyelination in MS.\n \n\n Unbuzzd Wellness Inc., the worldwide licensee of the Company’s asset, unbuzzd, a mix of supplements that has been clinically proven to both accelerate the metabolism of alcohol and reduce the symptoms of hangover, has commercialized unbuzzd in the United States; i...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B